Sustained plasma hepcidin suppression and iron elevation by Anticalin‐derived hepcidin antagonist in cynomolgus monkey
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Anaemia of chronic disease (ACD) has been linked to iron‐restricted erythropoiesis imposed by high circulating levels of hepcidin, a 25 amino acid hepatocyte‐derived peptide that controls systemic iron homeostasis. Here, we report the engineering of the human lipocalin‐derived, small protein‐based anticalin PRS‐080 hepcidin antagonist with high affinity and selectivity. Experimental Approach: Anticalin‐ and hepcidin‐specific pharmacokinetic (PK)/pharmacodynamic modelling (PD) was used to design and select the suitable drug candidate based on t1/2 extension and duration of hepcidin suppression. The development of a novel free hepcidin assay enabled accurate analysis of bioactive hepcidin suppression and elucidation of the observed plasma iron levels after PRS‐080‐PEG30 administration in vivo. Key Results: PRS‐080 had a hepcidin‐binding affinity of 0.07 nM and, after coupling to 30 kD PEG (PRS‐080‐PEG30), a t1/2 of 43 h in cynomolgus monkeys. Dose‐dependent iron mobilization and hepcidin suppression were observed after a single i.v. dose of PRS‐080‐PEG30 in cynomolgus monkeys. Importantly, in these animals, suppression of free hepcidin and subsequent plasma iron elevation were sustained during repeated s.c. dosing. After repeated dosing and followed by a treatment‐free interval, all iron parameters returned to pre‐dose values. Conclusions and Implications: In conclusion, we developed a dose‐dependent and safe approach for the direct suppression of hepcidin, resulting in prolonged iron mobilization to alleviate iron‐restricted erythropoiesis that can address the root cause of ACD. PRS‐080‐PEG30 is currently in early clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 4×
“Other strategies to reduce hepcidin expression with inhibitors of the bonemorphogenetic protein-6/haemojuvelin/ mothers against decapentaplegic homologue pathway or inhibitors of the IL-6/signal transducer and activator of transcription-3 pathway have been considered as well, since hepcidin expression is controlled by…”
BackgroundMethodInfluentialAnimal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Goetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., & Strong, R. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00708-6 · Cited by 1,355 · cited 1×
“Immobilized NGAL bound the bacterial siderophore Fe-enterobactin with subnanomolar affinity but did not bind hepcidin as expected based on its reported specificity (Goetz et al., 2002).”
BackgroundMcGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism
Andriopoulos Jr, B., Corradini, E., Xia, Y., Faasse, S. A., Chen, S., Grgurevic, L., Knutson, M. D., Pietrangelo, A., Vukicevic, S., Lin, H. Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.335 · Cited by 769
Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS
Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005) · Blood · doi:10.1182/blood-2005-03-1159 · Cited by 498
Self-citationHepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466 · cited 2×
“, 2004b) and thereby blocks iron export from macrophages and hepatocytes and iron uptake by duodenal enterocytes (Ganz and Nemeth, 2011).”
BackgroundIron Sequestration and Anemia of Inflammation
Ganz, T., & Nemeth, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.06.001 · Cited by 361
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352 · cited 2×
“Other strategies to reduce hepcidin expression with inhibitors of the bonemorphogenetic protein-6/haemojuvelin/ mothers against decapentaplegic homologue pathway or inhibitors of the IL-6/signal transducer and activator of transcription-3 pathway have been considered as well, since hepcidin expression is controlled by…”
BackgroundFleming, R. E., & Sly, W. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161296298 · Cited by 273 · cited 2×
“Multiple lines of evidence, both in preclinical models and humans, have revealed that functional iron deficiency in ACD can be attributed to increased concentrations of the main iron regulatory hormone hepcidin (De Falco et al., 2013; Fleming and Sly, 2001; Guo et al., 2013; Kemna et al., 2005; Roy et al., 2007).”
BackgroundSasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J., Winters, A., Juan, T., Li, H., Begley, C. G., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245977 · Cited by 251 · cited 1×
“In this regard, anti-hepcidin antibodies have been explored in in vivo models to modulate iron metabolism during anaemia of inflammation (Cooke et al., 2013; Krzyzanski et al., 2016; Sasu et al., 2010).”
BackgroundGuo, W., Bachman, E., Li, M., Roy, C. N., Blusztajn, J., Wong, S., Chan, S. Y., Serra, C., Jasuja, R., Travison, T. G., et al. (2013) · Aging Cell · doi:10.1111/acel.12052 · Cited by 192
Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation
Roy, C. N., Mak, H. H., Akpan, I., Losyev, G., Zurakowski, D., & Andrews, N. C. (2007) · Blood · doi:10.1182/blood-2006-10-051755 · Cited by 178 · cited 2×
“Multiple lines of evidence, both in preclinical models and humans, have revealed that functional iron deficiency in ACD can be attributed to increased concentrations of the main iron regulatory hormone hepcidin (De Falco et al., 2013; Fleming and Sly, 2001; Guo et al., 2013; Kemna et al., 2005; Roy et al., 2007).”
BackgroundSchwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158 · cited 2×
“…been studied using NOX-H94, an enantiomeric L-RNA aptamer (also called Spiegelmer), which resulted in ironmobilization in cynomolgus monkeys, healthy human volunteers and healthy volunteers with LPS-induced systemic inflammation (Boyce et al., 2016; Schwoebel et al., 2013; van Eijk et al., 2014).”
BackgroundMethodRoss, S. L., Tran, L., Winters, A., Lee, K.-J., Plewa, C., Foltz, I., King, C., Miranda, L. P., Allen, J., Beckman, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.017 · Cited by 145 · cited 1×
“The hepcidin–IREG1 pathway constitutes an interesting target in this regard (Nemeth, 2010; Ross et al., 2012; Sun et al., 2012).”
BackgroundA fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates
Cooke, K. S., Hinkle, B., Salimi-Moosavi, H., Foltz, I., King, C., Rathanaswami, P., Winters, A., Steavenson, S., Begley, C. G., Molineux, G., et al. (2013) · Blood · doi:10.1182/blood-2013-06-505792 · Cited by 113
van Eijk, L. T., John, A. S. E., Schwoebel, F., Summo, L., Vauléon, S., Zöllner, S., Laarakkers, C. M., Kox, M., van der Hoeven, J. G., Swinkels, D. W., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559484 · Cited by 110 · cited 1×
“…been studied using NOX-H94, an enantiomeric L-RNA aptamer (also called Spiegelmer), which resulted in ironmobilization in cynomolgus monkeys, healthy human volunteers and healthy volunteers with LPS-induced systemic inflammation (Boyce et al., 2016; Schwoebel et al., 2013; van Eijk et al., 2014).”
MethodSelf-citationBöser, P., Seemann, D., Liguori, M. J., Fan, L., Huang, L., Hafner, M., Popp, A., & Mueller, B. K. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9770-4 · Cited by 35 · cited 2×
“Other strategies to reduce hepcidin expression with inhibitors of the bonemorphogenetic protein-6/haemojuvelin/ mothers against decapentaplegic homologue pathway or inhibitors of the IL-6/signal transducer and activator of transcription-3 pathway have been considered as well, since hepcidin expression is controlled by…”
Background
Research works printed but not linked: 31
- 10.1111/bph.13883 · DOI · Paper page
- 10.1093/ndt/gfv302 · DOI · Paper page
- 10.2215/CJN.01420406 · DOI · Paper page
- 10.1111/bph.13433 · DOI · Paper page
- 10.1681/ASN.2014090922 · DOI
- 10.1111/bph.12856 · DOI · Paper page
- 10.3324/haematol.2012.075515 · DOI · Paper page
- 10.1007/s10456-015-9490-5 · DOI
- 10.1093/nar/gkx1121 · DOI · Paper page
- HohlbaumAM JensenK AllersdorferA BaehreA Bel AibaRS ChristianJet al. (2011).Exploiting lipocalin biochemistry for the treatment of allergy and asthma: discovery and characterization of an anti‐IL‐4RA therapeutic.C21. NEW TARGETS FOR ASTHMA THERAPY. American Thoracic Society. · doi:10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4065
- Home office, 1989, Animals (Scientific Procedures) act 1986, Code of Practice for the housing and care of animals used in scientific procedures, ISBN 0102107890
- 10.1007/s11095-010-0098-6 · DOI · Paper page
- 10.1021/ja806857r · DOI
- 10.1373/clinchem.2010.149187 · DOI · Paper page
- 10.1208/s12248-016-9886-1 · DOI
- 10.1371/journal.pone.0075518 · DOI · Paper page
- 10.1016/j.kint.2015.10.002 · DOI · Paper page
- 10.1371/journal.pone.0083232 · doi:10.1371/journal.pone.0083232
- 10.1155/2010/750643 · DOI · Paper page
- 10.1126/science.1104742 · DOI · Paper page
- 10.1152/ajprenal.2000.279.1.F84 · DOI
- 10.1158/1535-7163.MCT-13-0318 · DOI
- 10.1016/j.kint.2016.07.019 · DOI · Paper page
- 10.1053/j.ajkd.2015.12.020 · DOI · Paper page
- Rostoker G, 2012, Hemodialysis‐associated hemosiderosis in the era of erythropoiesis‐stimulating agents: a MRI study, Am J Med, 125, e1
- 10.1006/jmbi.2000.3646 · DOI
- 10.1073/pnas.0813399106 · DOI
- 10.1681/ASN.2015010052 · DOI
- 10.1002/ajh.23110 · DOI · Paper page
- 10.1182/blood-2007-09-111567 · DOI · Paper page
- 10.1208/s12248-010-9222-0 · DOI
Cited by
Iron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
Ganz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Self-citationUnraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing
Diepeveen, L. E., Laarakkers, C. M., Peters, H. P. E., van Herwaarden, A. E., Groenewoud, H., IntHout, J., Wetzels, J. F., van Swelm, R. P. L., & Swinkels, D. W. (2019) · Pharmaceuticals · doi:10.3390/ph12030123 · Cited by 11
“These compounds display a high affinity for hepcidin and therefore specifically for the assessment of hepcidin antagonist efficiency, the remaining free, non-antagonist bound hepcidin should be quantified [51] rather than total hepcidin [52–54].”
BackgroundSelf-citation
Metadata
- Authors
- Hohlbaum, A. M., Gille, H., Trentmann, S., Kolodziejczyk, M., Rattenstetter, B., Laarakkers, C. M., Katzmann, G., Christian, H. J., Andersen, N., Allersdorfer, A., Olwill, S. A., Meibohm, B., Audoly, L. P., Swinkels, D. W., & van Swelm, R. P. L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2018-02-23
- Volume
- 175
- Issue
- 7
- Pages
- 1054-1065
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2782555014
- Cited by
- 42
- References
- 20
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- European Commission in the context of the FP7 health programme Eurocalin (HEALTH-F4-2011-278408)
- Pieris Therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.